Product information: SmPC, labelling and package leaflet
Product information is the approved SmPC, labelling and package leaflet of a medicine: the texts that say how it is used and what appears on the pack.
Also known as: PI, product information annexes
4 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Consists of
- SmPC, labelling and package leaflet
- Legal basis
- Articles 8(3)(j), 11, 54 to 59 and 61 of Directive 2001/83/EC
- Centralised
- Annexes I to III of the Commission decision, in every EU language
- Changed by
- Variation, or Article 61(3) notification where the SmPC is not affected
How it works
Product information is the collective term for the three texts approved with every marketing authorisation: the summary of product characteristics for healthcare professionals, the labelling on the outer and immediate packaging, and the package leaflet for patients. Article 8(3)(j) of Directive 2001/83/EC requires an application to include the SmPC, a mock-up of the outer and immediate packaging and the package leaflet. Article 11 sets the content of the SmPC, Articles 54 to 57 that of the labelling and Article 59 that of the leaflet. The authority approves the texts, and Article 61 requires it to refuse an authorisation if the labelling or leaflet does not comply or is not in accordance with the SmPC.
In the centralised procedure the product information forms the annexes to the Commission decision: Annex I is the SmPC, Annex II lists the manufacturers responsible for batch release and the conditions of the authorisation, Annex IIIA is the labelling and Annex IIIB the package leaflet. They are written on the QRD template and exist in every official EU language plus Norwegian and Icelandic. The English text is agreed during the assessment; the translations are submitted five days after the CHMP opinion, reviewed by the Member States and finalised before the Commission decision. In mutual recognition and decentralised procedures the reference and concerned member states agree a common English text and the national translations follow in the national phase, so each Member State ends up with its own approved national version.
The three texts depend on each other. The leaflet and the labelling must be in accordance with the SmPC, and advertising must comply with it. A change therefore rarely touches one document: a new warning in section 4.4 of the SmPC usually changes the leaflet, and a new strength changes all three and the artwork. Changes to the SmPC are variations. Changes to the labelling or leaflet that are not connected with the SmPC go through an Article 61(3) notification. The outcome of a PSUSA or a referral arrives as agreed wording that every affected holder must implement by a set deadline.
What goes wrong
The SmPC is updated and the leaflet or the carton is not; national versions of the same product drift apart because variations were implemented in some markets and not in others; translations are produced from an outdated English text; the approved text and the printed artwork are kept in different systems, so nobody can show which approved version a pack follows; and a template update or a safety outcome becomes a portfolio-wide audit because versions are not tracked by product, market and language. For generics the text must also follow the reference product wherever it is not protected, so every change to the reference product's information is a change to plan for.
Timing
Day 210
CHMP opinion with the agreed English product information.
Day 215
Translations in all EU languages submitted.
Day 229
Member States send their linguistic review comments.
Day 235
Final translations submitted to EMA.
In the centralised procedure the translations of the product information are submitted at Day 215, five days after the CHMP opinion. Member States send their linguistic comments by Day 229 and the final texts are due by Day 235, ahead of the Commission decision. In mutual recognition and decentralised procedures the national translations are due within days of the close of the procedure, and the national authorisations follow within 30 days.
What teams do with it in Regunaut
Jobs in the platform that turn on Product information, each part of a wider workflow.
- Workbench quick task · LabellingCompare EU and US labellingMap the structure and purpose of SmPC and US PI sections.Part of ePI & labelling
- Workbench quick task · LabellingCheck core safety information alignmentFind differences between local labelling and the company core text.Part of ePI & labelling
What the 2026 EU pharma package changes
Under the new pharma package (not yet in force), the package leaflet must be provided on paper and electronically, which makes structured electronic product information part of the same set of texts; see ePI changes.
Product information: common questions
What does product information include?
The summary of product characteristics, the labelling of the outer and immediate packaging, and the package leaflet. In the centralised procedure these are Annex I, Annex IIIA and Annex IIIB of the Commission decision, with Annex II listing the manufacturers responsible for batch release and the conditions of the authorisation.
What is the difference between the SmPC and the package leaflet?
The SmPC is written for healthcare professionals and follows the section order in Article 11 of Directive 2001/83/EC. The package leaflet is written for patients, goes in the pack, follows Article 59 and must be drawn up in accordance with the SmPC. A change to the SmPC that matters to patients therefore needs a matching change to the leaflet.
How is product information changed after authorisation?
Changes to the SmPC, and changes to the labelling or leaflet connected with them, are made by variation. Changes to the labelling or leaflet that are not connected with the SmPC are notified under Article 61(3) of Directive 2001/83/EC and may be made if the authority has not objected within 90 days.